Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

CRISPR/Cas9-Mediated In Situ Correction of LAMB3 Gene in Keratinocytes Derived from a Junctional Epidermolysis Bullosa Patient

  • Benati, Daniela
  • Miselli, Francesca
  • Cocchiarella, Fabienne
  • Patrizi, Clarissa
  • Carretero Trillo, Marta
  • Baldassarri, Samantha
  • Ammendola, Virginia
  • Has, Cristina
  • Colloca, Stefano
  • Río Nechaevsky, Marcela del
  • Larcher Laguzzi, Fernando
  • Recchia, Alessandra
Deficiency of basement membrane heterotrimeric laminin 332 component, coded by LAMA3, LAMB3, and LAMC2 genes, causes junctional epidermolysis bullosa (JEB), a severe skin adhesion defect. Herein, we report the first application of CRISPR/Cas9-mediated homology direct repair (HDR) to in situ restore LAMB3 expression in JEB keratinocytes in vitro and in immunodeficient mice transplanted with genetically corrected skin equivalents. We packaged an adenovector carrying Cas9/guide RNA (gRNA) tailored to the intron 2 of LAMB3 gene and an integration defective lentiviral vector bearing a promoterless quasi-complete LAMB3 cDNA downstream a splice acceptor site and flanked by homology arms. Upon genuine HDR, we exploited the in vitro adhesion advantage of laminin 332 production to positively select LAMB3-expressing keratinocytes. HDR and restored laminin 332 expression were evaluated at single-cell level. Notably, monoallelic-targeted integration of LAMB3 cDNA was sufficient to in vitro recapitulate the adhesive property, the colony formation typical of normal keratinocytes, as well as their cell growth. Grafting of genetically corrected skin equivalents onto immunodeficient mice showed a completely restored dermal-epidermal junction. This study provides evidence for efficient CRISPR/Cas9-mediated in situ restoration of LAMB3 expression, paving the way for ex vivo clinical application of this strategy to laminin 332 deficiency., This work was supported by grants from the European Commission ( FP7, PERSIST ) and the Italian Ministry of University and Research. M.D.R. and F.L. are supported by Spanish grants SAF2013-43475-R and SAF2017-86810-R from the Ministry of Economy and Competitiveness and PI14/00931 and PI17/01747 from Instituto de Salud Carlos III co-funded with European Regional Development Funds (ERDF).
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

International network of cancer genome projects

  • Campo Güerri, Elias
  • Sanjosé Llongueras, Silvia de
  • Montserrat Costa, Emilio
  • Jares Gerboles, Pedro
  • Beà Bobet, Sílvia M.
  • Cancer Genome Consortium
The International Cancer Genome Consortium (ICGC) was launched to coordinate large-scale cancer genome studies in tumors from 50 different cancer types and/or subtypes that are of clinical and societal importance across the globe. Systematic studies of over 25,000 cancer genomes at the genomic, epigenomic, and transcriptomic levels will reveal the repertoire of oncogenic mutations, uncover traces of the mutagenic influences, define clinically-relevant subtypes for prognosis and therapeutic management, and enable the development of new cancer therapies.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

International network of cancer genome projects

  • Campo Güerri, Elias
  • Sanjosé Llongueras, Silvia de
  • Montserrat Costa, Emilio
  • Jares Gerboles, Pedro
  • Beà Bobet, Sílvia M.
  • Cancer Genome Consortium
The International Cancer Genome Consortium (ICGC) was launched to coordinate large-scale cancer genome studies in tumors from 50 different cancer types and/or subtypes that are of clinical and societal importance across the globe. Systematic studies of over 25,000 cancer genomes at the genomic, epigenomic, and transcriptomic levels will reveal the repertoire of oncogenic mutations, uncover traces of the mutagenic influences, define clinically-relevant subtypes for prognosis and therapeutic management, and enable the development of new cancer therapies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeted gene therapy and cell reprogramming in Fanconi anemia

  • Río, Paula
  • Baños, Rocío
  • Lombardo, Angelo
  • Quintana-Bustamante, Oscar|||0000-0002-6869-7006
  • Alvarez, Lara
  • Garate, Zita
  • Genovese, Pietro
  • Almarza, Elena
  • Valeri, Antonio
  • Díez, Begoña
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Torres, Yaima
  • Trujillo, Juan P.
  • Murillas, Rodolfo
  • Segovia, Jose C.|||0000-0003-4101-6124
  • Samper, Enrique
  • Surralles, Jordi|||0000-0002-4041-7519
  • Gregory, Philip D.
  • Holmes, Michael C.
  • Naldini, Luigi
  • Bueren, Juan|||0000-0002-3228-7013
Gene targeting is progressively becoming a realistic therapeutic alternative in clinics. It is unknown, however, whether this technology will be suitable for the treatment of DNA repair deficiency syndromes such as Fanconi anemia (FA), with defects in homology-directed DNA repair. In this study, we used zinc finger nucleases and integrase-defective lentiviral vectors to demonstrate for the first time that FANCA can be efficiently and specifically targeted into the AAVS1 safe harbor locus in fibroblasts from FA-A patients. Strikingly, up to 40% of FA fibroblasts showed gene targeting 42 days after gene editing. Given the low number of hematopoietic precursors in the bone marrow of FA patients, gene-edited FA fibroblasts were then reprogrammed and re-differentiated toward the hematopoietic lineage. Analyses of gene-edited FA-iPSCs confirmed the specific integration of FANCA in the AAVS1 locus in all tested clones. Moreover, the hematopoietic differentiation of these iPSCs efficiently generated disease-free hematopoietic progenitors. Taken together, our results demonstrate for the first time the feasibility of correcting the phenotype of a DNA repair deficiency syndrome using gene-targeting and cell reprogramming strategies.